ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Matías Estarás

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3462-7904; OpenAlex author ID A5023685003. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Patricia Santofimia‐Castaño · 2 shared papers, 2025–2026 · strength 0.58
- Paper Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsic… DOI 10.1016/j.ijbiomac.2025.149435 ↗
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
Juan Iovanna · 2 shared papers, 2025–2026 · strength 0.58
- Paper Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsic… DOI 10.1016/j.ijbiomac.2025.149435 ↗
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
José L. Neira · 1 shared paper, 2026 · strength 0.33
- Paper Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsic… DOI 10.1016/j.ijbiomac.2025.149435 ↗
María Gabriela Álvarez-Rodríguez · 1 shared paper, 2026 · strength 0.33
- Paper Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsic… DOI 10.1016/j.ijbiomac.2025.149435 ↗
Antonio González · 1 shared paper, 2021 · strength 0.28
- Paper Modulation of cell physiology under hypoxia in pancreatic cancer. DOI 10.3748/wjg.v27.i28.4582 ↗
Analía Meilerman Abuelafia · 1 shared paper, 2025 · strength 0.25
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
Nicolas Alejandro Fraunhoffer · 1 shared paper, 2025 · strength 0.25
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
Eduardo Chuluyán · 1 shared paper, 2025 · strength 0.25
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
Raul A. Urrutia · 1 shared paper, 2025 · strength 0.25
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
Gwen Alyce Lomberk · 1 shared paper, 2025 · strength 0.25
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
Nelson Dusetti · 1 shared paper, 2025 · strength 0.25
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗
Daniel Grasso · 1 shared paper, 2025 · strength 0.25
- Paper KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adeno… DOI 10.1016/j.tranon.2025.102421 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.